I am loving this run-up pre earnings even though this board is a ghost town. If I have converse with myself, so be it. Go MCHX!
C
Why do you suppose Marchex is trying to buy back shares? All I can think of is that the price is currently so low and they are only offering $1.82 - 1.96 per share. It seems to me they think there may be some reason buying the shares down here is a good thing for the company. Frankly, I would be selling at a loss so I am not tempted.
e
EDENBROOK CAPITALS Jonathan BROLIN Is playing options of MCHX as well as buying the stock outright. A little hedge can’t hurt. Long term I think the stick can get back into the $5 range before spring I’m hoping for $7 a share.
who owns this stock ? is it a good long term hold? thanks, Chris
K
what a great steady slow 3 week climb.....$1.13 increase at a very nice rate of climb and volume....
e
MCHX up again. Who is buying ?
K
I'm actually green for the first time in a year - what is the catalyst? who is buying?
e
2018 Marchex, Inc. Office of the Chairman and Office of the CEO 520 Pike Street Suite 2000 Seattle, WA 98101 Attention: Anne Devereux-Mills, Russell Horowitz and Mike Arends
Dear Anne, Russ and Mike:
Edenbrook Capital, LLC (“Edenbrook,” “we,” or “us”) beneficially owns 5,360,495 shares of Class B common stock, par value $0.01 per share (the “Class B Stock”) of Marchex, Inc. (“Marchex,” or the “Company”), representing approximately 14.5% of the outstanding Class B Stock and approximately 12.0% of Company’s outstanding common stock, including its privately-held Class A common stock, par value $0.01 per share. Edenbrook has been a stockholder since the first quarter of 2015 and has steadily grown its position to become the Company’s largest institutional stockholder.
Over the nearly four years of ownership, we have seen the Company’s management team successfully transform Marchex from a primarily transactional business to a recurring revenue business focused on enterprise clients. In doing so, you have put Marchex on a path to long-term, profitable and cash-generative growth. While the path to getting to this point has not been linear, the progress has been profound, and accelerated significantly this year. Over the course of 2018 alone, the Company has executed several meaningful examples of capital allocation, including:
1) Paying a special dividend of $0.50 per share in March
2) Opportunistically repurchasing an insider block of 2.3mm shares at $2.43 per share in May
3) Acquiring Telmetrics, an enterprise call and text tracking analytics company, in November
4) Acquiring Callcap, a call monitoring and analytics company, in December
Additionally, for the first time, in its third quarter 2018 earnings release, Marchex provided stockholders with segment reporting that broke out the Company’s faster-growing, higher-margin analytics revenue, which is largely recurring in nature. This high quality, software-based business, when combined with the two acquisitions referenced above, positions the Company to have a growing analytics business with more than $50 million in revenue. With the faster growing, higher-margin business expected to be more than half revenue in 2019, we expect to see meaningful pull-through effects for the Company’s aggregate financial profile. As one might have expected from this segment reporting, stockholders enjoyed an initial bounce in the stock price after Marchex’s third quarter earnings report showed how strong the crown jewel analytics business has become.
Despite all of these positive developments, Marchex’s Class B Stock now trades at an enterprise value of less than $70 million. One way to look at Marchex’s trading price is to say that Marchex is being valued at less than 1.4x its high quality analytics revenue, with zero value being given to the $50 million in trailing twelve months revenue from the Company’s legacy marketplace business, its $100+ million net operating loss carryforward or any of the Company’s intellectual property, including the massive conversational data set built up over many years, which is both hard to replicate and is the source of value creation for new higher, margin, recurring products.
We believe Marchex’s trading price of $2.63 per share (as of December 21, 2018) demonstrates a substantial discount to comparable industry valuations. Similar analytics-based public companies are trading at 4-6 times revenue, while private companies are being financed at 6-10+ times revenue. If Marchex were valued at 3 times analytics revenue (which is still a substantial discount to the market and less than Marchex just paid for Callcap), and approximately $44 million in cash were factored in, this would yield a value today of approximately $4.65 per share, which is 75% above today’s trading price of $2.63 per share (as of December 21, 2018). Adding in discounted values for the legacy business and the NOL carryforward would yield another approximately $1.60 per share, totaling approximately $6.25 per share, more than double today’s price. Further, given the continued profitable growth of the business, we expect these values to continue to expand in the coming years.
While the market is currently missing out on the accretive, profitable changes you are making to the business, we remain steadfast supporters of your transformation and believe that in time, the value will shine through and shareholders will be rewarded for your efforts and value creation.
Sincerely,  Jonathan Brolin Managing Partner
M
Big Day as we approach earnings! Awesome price and volume! Only took 3 years
e
It’s such a shame that I’ve had the stock since March 2018!!! It’s been dead money good thing I had other capital to make cash . I really thought that when management Eden Brook capital we’re going to be buying up shares that this was going to start moving
K
wonder if the telmetrics acquisition can get me to even? woulda been better off shoving my money in a food saver bag and putting it in the freezer for a year -
D
Why is this board so inactive?----nothing to talk about?
e
Marchex, Inc. (NASDAQ: MCHX) has been undergoing a period of transformation and should become a growth business in 2019 and beyond, according to Roth Capital. The Analyst Roth Capital’s Darren Aftahi upgraded Marchex from Neutral to Buy and raised the price target from $3.40 to $7. The Thesis Marchex’s fundamentals have started gaining traction, and both its business and shares have become compelling, Aftahi said in the Sunday upgrade note. An uptrend is underway in speech-based analytics revenue, the analyst said. Organic growth in analytics revenue was around 17 percent year-on-year and 8-percent sequentially in Q3, he said. Analytics revenue has also been boosted by recent acquisitions. With this segment beginning to comprise a major portion of Marchex's revenue base, the company is becoming “a more compelling story given its growth profile; tiered-subscription-based recurring revenue, and higher margin profile,” Aftahi said. Marchex has gathered a massive database of first-party conversational analytics data, according to Roth Capital. Given this and Marchex’s scale, with more than 1,200 brands, the company has differentiated itself, Aftahi said. While Marchex can use its core dataset to train models and create unique models for clients, other platforms need to purchase the datasets from third-parties in order to train models, the analyst said.
e
Im happy with the Quarter. Lets see how Wall street responds. They beat the streets estimate
K
hope this gain holds.......
Y
MCHX is up 5.49% to 2.88
K
bought recently to get this nice dividend - last day to get in for .50 per share.........
e
So who is buying this market? What’s your other plays besides FCHS? I like $MSFT and a small cap $MCHX
M
With the two Q4 acquisitions (add revenue/up guidance), new products launching (50% of their employees are R&D), Trimming Seattle workforce, and company buying back largest shareholder Hanauer's 2mm shares, MCHX should have a very nice 2019. This has been stuck in 2's and 3's way too long...
https://flashalert.me/?symbol=MCHX&source=SEC&referer=https://stocktwits.com/&url=https://www.sec.gov/Archives/edgar/data/1224133/000106299319003705/xslF345X03/form4.xml&s3=MCHX/2019-09-19/20-30-45_298810/4/form4.xml
Marchex, Inc.
Office of the Chairman and Office of the CEO
520 Pike Street
Suite 2000
Seattle, WA 98101
Attention: Anne Devereux-Mills, Russell Horowitz and Mike Arends
Dear Anne, Russ and Mike:
Edenbrook Capital, LLC (“Edenbrook,” “we,” or “us”) beneficially owns 5,360,495 shares of Class B common stock, par value $0.01 per share (the “Class B Stock”) of Marchex, Inc. (“Marchex,” or the “Company”), representing approximately 14.5% of the outstanding Class B Stock and approximately 12.0% of Company’s outstanding common stock, including its privately-held Class A common stock, par value $0.01 per share. Edenbrook has been a stockholder since the first quarter of 2015 and has steadily grown its position to become the Company’s largest institutional stockholder.
Over the nearly four years of ownership, we have seen the Company’s management team successfully transform Marchex from a primarily transactional business to a recurring revenue business focused on enterprise clients. In doing so, you have put Marchex on a path to long-term, profitable and cash-generative growth. While the path to getting to this point has not been linear, the progress has been profound, and accelerated significantly this year. Over the course of 2018 alone, the Company has executed several meaningful examples of capital allocation, including:
1)
Paying a special dividend of $0.50 per share in March
2)
Opportunistically repurchasing an insider block of 2.3mm shares at $2.43 per share in May
3)
Acquiring Telmetrics, an enterprise call and text tracking analytics company, in November
4)
Acquiring Callcap, a call monitoring and analytics company, in December
Additionally, for the first time, in its third quarter 2018 earnings release, Marchex provided stockholders with segment reporting that broke out the Company’s faster-growing, higher-margin analytics revenue, which is largely recurring in nature. This high quality, software-based business, when combined with the two acquisitions referenced above, positions the Company to have a growing analytics business with more than $50 million in revenue. With the faster growing, higher-margin business expected to be more than half revenue in 2019, we expect to see meaningful pull-through effects for the Company’s aggregate financial profile. As one might have expected from this segment reporting, stockholders enjoyed an initial bounce in the stock price after Marchex’s third quarter earnings report showed how strong the crown jewel analytics business has become.
Despite all of these positive developments, Marchex’s Class B Stock now trades at an enterprise value of less than $70 million. One way to look at Marchex’s trading price is to say that Marchex is being valued at less than 1.4x its high quality analytics revenue, with zero value being given to the $50 million in trailing twelve months revenue from the Company’s legacy marketplace business, its $100+ million net operating loss carryforward or any of the Company’s intellectual property, including the massive conversational data set built up over many years, which is both hard to replicate and is the source of value creation for new higher, margin, recurring products.
We believe Marchex’s trading price of $2.63 per share (as of December 21, 2018) demonstrates a substantial discount to comparable industry valuations. Similar analytics-based public companies are trading at 4-6 times revenue, while private companies are being financed at 6-10+ times revenue. If Marchex were valued at 3 times analytics revenue (which is still a substantial discount to the market and less than Marchex just paid for Callcap), and approximately $44 million in cash were factored in, this would yield a value today of approximately $4.65 per share, which is 75% above today’s trading price of $2.63 per share (as of December 21, 2018). Adding in discounted values for the legacy business and the NOL carryforward would yield another approximately $1.60 per share, totaling approximately $6.25 per share, more than double today’s price. Further, given the continued profitable growth of the business, we expect these values to continue to expand in the coming years.
While the market is currently missing out on the accretive, profitable changes you are making to the business, we remain steadfast supporters of your transformation and believe that in time, the value will shine through and shareholders will be rewarded for your efforts and value creation.
Sincerely,

Jonathan Brolin
Managing Partner
The Analyst
Roth Capital’s Darren Aftahi upgraded Marchex from Neutral to Buy and raised the price target from $3.40 to $7.
The Thesis
Marchex’s fundamentals have started gaining traction, and both its business and shares have become compelling, Aftahi said in the Sunday upgrade note.
An uptrend is underway in speech-based analytics revenue, the analyst said. Organic growth in analytics revenue was around 17 percent year-on-year and 8-percent sequentially in Q3, he said.
Analytics revenue has also been boosted by recent acquisitions. With this segment beginning to comprise a major portion of Marchex's revenue base, the company is becoming “a more compelling story given its growth profile; tiered-subscription-based recurring revenue, and higher margin profile,” Aftahi said.
Marchex has gathered a massive database of first-party conversational analytics data, according to Roth Capital.
Given this and Marchex’s scale, with more than 1,200 brands, the company has differentiated itself, Aftahi said.
While Marchex can use its core dataset to train models and create unique models for clients, other platforms need to purchase the datasets from third-parties in order to train models, the analyst said.
I like $MSFT and a small cap $MCHX